全文获取类型
收费全文 | 2762682篇 |
免费 | 199490篇 |
国内免费 | 7708篇 |
专业分类
耳鼻咽喉 | 37312篇 |
儿科学 | 91886篇 |
妇产科学 | 76988篇 |
基础医学 | 390969篇 |
口腔科学 | 74870篇 |
临床医学 | 249499篇 |
内科学 | 546286篇 |
皮肤病学 | 66488篇 |
神经病学 | 226180篇 |
特种医学 | 106905篇 |
外国民族医学 | 768篇 |
外科学 | 414902篇 |
综合类 | 55584篇 |
现状与发展 | 6篇 |
一般理论 | 1098篇 |
预防医学 | 209015篇 |
眼科学 | 61387篇 |
药学 | 201258篇 |
8篇 | |
中国医学 | 5800篇 |
肿瘤学 | 152671篇 |
出版年
2019年 | 21921篇 |
2018年 | 31315篇 |
2017年 | 24037篇 |
2016年 | 27924篇 |
2015年 | 31419篇 |
2014年 | 43046篇 |
2013年 | 64765篇 |
2012年 | 85420篇 |
2011年 | 90022篇 |
2010年 | 54687篇 |
2009年 | 52362篇 |
2008年 | 84056篇 |
2007年 | 89399篇 |
2006年 | 91088篇 |
2005年 | 87015篇 |
2004年 | 83873篇 |
2003年 | 80949篇 |
2002年 | 77923篇 |
2001年 | 135213篇 |
2000年 | 138379篇 |
1999年 | 116476篇 |
1998年 | 32997篇 |
1997年 | 29507篇 |
1996年 | 29686篇 |
1995年 | 28781篇 |
1994年 | 26403篇 |
1993年 | 24702篇 |
1992年 | 89890篇 |
1991年 | 86481篇 |
1990年 | 83738篇 |
1989年 | 80929篇 |
1988年 | 74036篇 |
1987年 | 72414篇 |
1986年 | 67744篇 |
1985年 | 64647篇 |
1984年 | 48010篇 |
1983年 | 40580篇 |
1982年 | 24103篇 |
1981年 | 21375篇 |
1979年 | 42070篇 |
1978年 | 29692篇 |
1977年 | 25217篇 |
1976年 | 23234篇 |
1975年 | 24853篇 |
1974年 | 29272篇 |
1973年 | 27909篇 |
1972年 | 26164篇 |
1971年 | 24193篇 |
1970年 | 22344篇 |
1969年 | 21394篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
Karen Kayser Ariel Washington Lesley M. Harris Barbara Head 《Journal of psychosocial oncology》2021,39(1):17-34
Abstract
Purpose
Financial hardship can be a major cause of distress among persons with cancer, resulting in chronic stress and impacting physical and emotional health. This paper provides an analysis of the lived experience of cancer patients’ financial hardship from diagnosis to post-treatment. 相似文献23.
24.
25.
Boffa Joseph W. Tock Jamie L. Morabito Danielle M. Schmidt Norman B. 《Cognitive therapy and research》2022,46(5):1016-1029
Cognitive Therapy and Research - Despite interest in psychological inflexibility as a marker of suicide risk, no measure of psychological inflexibility specific to SI exists. The present study... 相似文献
26.
27.
28.
29.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
30.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献